Platelet function in hypertension

Blood Cells, Molecules, and Diseases

Volumn 42, Issue 1, 2009, Pages 38-43

  El Haouari, Mohammed ^a   Rosado, Juan A ^b  

^a FACULTÉ DES SCIENCES   (Morocco)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Ca2+ signaling; Hypertension; Nitric oxide; Platelets; Reactive oxygen species

Indexed keywords

CALCIUM; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TYROSINE;

ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CALCIUM SIGNALING; DISEASE COURSE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE;

BIOLOGICAL MARKERS; BLOOD PLATELETS; CALCIUM; CALCIUM SIGNALING; HUMANS; HYPERTENSION; NITRIC OXIDE; OXIDATIVE STRESS; PLATELET ACTIVATION; REACTIVE OXYGEN SPECIES;

EID: 57949095962     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2008.07.003     Document Type: Article

References (134)

1. Fuster V., Badimon L., Badimon J.J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 326 (1992) 242-250
2. Diodati J.G., Cannon R.O., and Hussain N. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am. J. Cardiol. 75 (1995) 443-448
3. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
4. Weyrich A., Cipollone F., Mezzetti A., et al. Platelets in atherothrombosis: new and evolving roles. Curr. Pharm. Des. 13 (2007) 1685-1691
5. Vorchheimer D.A., and Becker R. Platelets in atherothrombosis. Mayo Clin. Proc. 81 (2006) 59-68
6. Hernandez Hernandez R., Carvajal A.R., Guerrero Pajuelo J., et al. The effect of doxazosin on platelet aggregation in normotensive subjects and patients with hypertension: an in vitro study. Am. Heart J. 121 (1991) 389-394
7. Andrioli G., Ortolani R., Fontana L., et al. Study of platelet adhesion in patients with uncomplicated hypertension. J. Hypertens. 14 (1996) 1215-1221
8. Somova L., and Mufunda J. Platelet activity and salt sensitivity in the pathogenesis of systemic (essential) hypertension in black Africans. Clin. Exp. Hypertens. 15 (1993) 781-796
9. Punda A., Polic S., Rumboldt Z., et al. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. Croat. Med. J. 46 (2005) 219-224
10. Frangos S.G., Gahtan V., and Sumpio B. Localization of atherosclerosis: role of hemodynamics. Arch. Surg. 134 (1999) 1142-1149
11. 2+] is increased in the platelets of spontaneously hypertensive rats and essential hypertensive patients. Clin. Sci. (Lond). 68 (1985) 179-184
12. Erne P., Bolli P., Burgisser E., et al. Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N. Engl. J. Med. 310 (1984) 1084-1088
13. Camilletti A., Moretti N., Giacchetti G., et al. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am. J. Hypertens. 14 (2001) 382-386
14. Blann A.D., Lip G.Y., Islim I.F., et al. Evidence of platelet activation in hypertension. J. Hum. Hypertens. 11 (1997) 607-609
15. Preston R.A., Jy W., Jimenez J.J., et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 41 (2003) 211-217
16. Tran H., and Anand S.S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 292 (2004) 1867-1874
17. Duhamel T.A., Xu Y.J., Arneja A.S., et al. Targeting platelets for prevention and treatment of cardiovascular disease. Expert. Opin. Ther. Targets 11 (2007) 1523-1533
18. Holmsen H. Platelet metabolism and activation. Semin. Hematol. 22 (1985) 219-240
19. 2+ concentrations in essential hypertension. Hypertension 22 (1993) 853-862
20. Mohle R., Green D., Moore M.A., et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 663-668
21. Blann A.D., Belgore F.M., Constans J., et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am. J. Cardiol. 87 (2001) 1160-1163
22. Nadar S.K., Blann A.D., and Lip G.Y. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J. Intern. Med. 256 (2004) 331-337
23. Nadar S.K., Blann A.D., Kamath S., et al. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J. Am. Coll. Cardiol. 44 (2004) 415-422
24. Nadar S.K., Lip G.Y., and Blann A.D. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The West Birmingham Stroke Project. Thromb. Haemost. 92 (2004) 1342-1348
25. Siebers R., and Maling T. Mean platelet volume in human essential hypertension. J. Hum. Hypertens. 9 (1995) 207
26. Nityanand S., Pande I., Bajpai V.K., et al. Platelets in essential hypertension. Thromb. Res. 72 (1993) 447-454
27. Barradas M.A., O'Donoghue S., and Mikhailidis D.P. Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo. 6 (1992) 629-634
28. Stohlawetz P., Hergovich N., Stiegler G., et al. Differential induction of P-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble P-selectin. Transfusion 38 (1998) 24-30
29. Jagroop I.A., Clatworthy I., Lewin J., et al. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 11 (2000) 28-32
30. Endler G., Klimesch A., Sunder-Plassmann H., et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br. J. Haematol. 117 (2002) 399-404
31. Chapman E.S., Sorette M., Hetherington E., et al. A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination. Thromb. Haemost. 89 (2003) 1004-1015
32. Pechan J., and Okrucka A. Diltiazem inhibits the spontaneous platelet aggregation in essential hypertension. Cardiology 79 (1991) 116-119
33. Kjeldsen S.E., Gjesdal K., Eide I., et al. Increased beta-thromboglobulin in essential hypertension: interactions between arterial plasma adrenaline, platelet function and blood lipids. Acta Med. Scand. 213 (1983) 369-373
34. Nomura S., Kanazawa S., and Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J. Hum. Hypertens. 16 (2002) 539-547
35. Chu S., Zhao G., and Du J. Inherited defect of platelet nitric oxide synthase activity in essential hypertension. Zhonghua Nei Ke Za Zhi 36 (1997) 584-586
36. Oshima T., Matsuura H., Matsumoto K., et al. Role of cellular calcium in salt sensitivity of patients with essential hypertension. Hypertension 11 (1988) 703-707
37. Paul B.Z., Daniel J.L., and Kunapuli S.P. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J. Biol. Chem. 274 (1999) 28293-28300
38. Michel M.C., Brodde O.E., and Insel P.A. Peripheral adrenergic receptors in hypertension. Hypertension 16 (1990) 107-120
39. Ariyoshi H., Aono Y., Tsuji Y., et al. Role of cytoplasmic calcium in platelet aggregation. Int. Angiol. 21 (2002) 134-137
40. do Ceu Monteiro M., Sansonetty F., Goncalves M.J., et al. Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41. Cytometry 35 (1999) 302-310
41. 2+ transport ATPase system. Platelets 8 (1997) 5-14
42. 2+ mobilization and aggregation in platelets from type 2 diabetic patients. Biochem. Biophys. Res. Commun. 333 (2005) 794-802
43. Labios M., Martinez M., Gabriel F., et al. Cytoplasmic free calcium mobilization in platelets, expression of P-selectin, phosphatidylserine, and microparticle formation, measured by whole blood flow cytometry, in hypertensive patients. Effect of doxazosin GITS. Thromb. Res. 117 (2006) 403-409
44. +-ATPases in human platelets. Biochem. J. 390 (2005) 243-252
45. 2+ compartments show differential sensitivity to thrombin, ADP and vasopressin in human platelets. Cell. Signal. 18 (2006) 373-381
46. 2+ stores in platelets, as identified by their differential sensitivity to 2,5-di-(tert-butyl)-1,4-benzohydroquinone and thapsigargin. Biochem. J. 310 (1995) 449-452
47. 2+ ATPase isoforms are expressed in a cell type? A growing family of membrane proteins illustrated by studies in platelets. Platelets 16 (2005) 133-150
48. Redondo P.C., Salido G.M., Pariente J.A., et al. SERCA2b and 3 play a regulatory role in store-operated calcium entry in human platelets. Cell. Signal. 20 (2008) 337-346
49. Rosado J.A., Jenner S., and Sage S.O. A role for the actin cytoskeleton in the initiation and maintenance of store-mediated calcium entry in human platelets. Evidence for conformational coupling. J. Biol. Chem. 275 (2000) 7527-7533
50. 2+-ATPase by small GTPases and phosphoinositides in human platelets. J. Biol. Chem. 275 (2000) 19529-19535
51. Oshima T., Young E.W., Bukoski R.D., et al. Abnormal calcium handling by platelets of spontaneously hypertensive rats. Hypertension 15 (1990) 606-611
52. 3H] arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochem. J. 235 (1986) 869-877
53. Lau K., and Eby B. The role of calcium in genetic hypertension. Hypertension 7 (1985) 657-667
54. Buhler F.R., and Resink T.J. Platelet abnormalities and the pathophysiology of essential hypertension. Experientia 44 (1988) 94-97
55. Young E.W., Bukoski R.D., and McCarron D.A. Calcium metabolism in experimental hypertension. Proc. Soc. Exp. Biol. Med. 187 (1988) 123-141
56. Lechi A., Lechi C., Bonadonna G., et al. Increased basal and thrombin-induced free calcium in platelets of essential hypertensive patients. Hypertension 9 (1987) 230-235
57. Haller H., Ludersdorf M., Lenz T., et al. Changes in sensitivity to angiotensin II in platelets. J. Cardiovasc. Pharmacol. 10 (1987) S44-47
58. 2+ in essential hypertension. Am. J. Physiol. 275 (1998) R574-579
59. 2+ is not increased in stroke-prone spontaneously hypertensive rats: comparative study with spontaneously hypertensive rats. Hypertension 27 (1996) 1312-1317
60. Haynes D.H. Effects of cyclic nucleotides and protein kinases on platelet calcium homeostasis and mobilization. Platelets 4 (1993) 231-242
61. Blockmans D., Deckmyn H., and Vermylen J. Platelet activation. Blood Rev. 9 (1995) 143-156
62. 2+ entry. Arch. Biochem. Biophys. 465 (2007) 16-25
63. Varani K., Gessi S., Caiazza A., et al. Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Br. J. Clin. Pharmacol. 47 (1999) 167-172
64. Larsson P.T., Wallen N.H., Martinsson A., et al. Significance of platelet beta-adrenoceptors for platelet responses in vivo and in vitro. Thromb. Haemost. 68 (1992) 687-693
65. Dean W.L., Pope J.E., Brier M.E., et al. Platelet calcium transport in hypertension. Hypertension 23 (1994) 31-37
66. 2+-ATPase in hypertension. Hypertension 35 (2000) 103-107
67. Bredt D.S., and Snyder S.H. Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 63 (1994) 175-195
68. Azuma H., Ishikawa M., and Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88 (1986) 411-415
69. 2+ stores. Circ. Res. 84 (1999) 201-209
70. Panza J.A., Casino P.R., Badar D.M., et al. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 87 (1993) 1475-1481
71. Panza J.A., Casino P.R., Kilcoyne C.M., et al. A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87 (1993) 1468-1474
72. Suzuki Y., Yoshimaru T., Matsui T., et al. Fc epsilon RI signaling of mast cells activates intracellular production of hydrogen peroxide: role in the regulation of calcium signals. J. Immunol. 171 (2003) 6119-6127
73. Redondo P.C., Salido G.M., Pariente J.A., et al. Dual effect of hydrogen peroxide on store-mediated calcium entry in human platelets. Biochem. Pharmacol. 67 (2004) 1065-1076
74. Rosado J.A., Redondo P.C., Salido G.M., et al. Hydrogen peroxide generation induces pp60src activation in human platelets: evidence for the involvement of this pathway in store-mediated calcium entry. J. Biol. Chem. 279 (2004) 1665-1675
75. 2 and oxidation of sulphydryl groups. Arch. Biochem. Biophys. 452 (2006) 9-16
76. Grenegard M., and lindstrom E.G. Reactive oxygen species derived from platelets reduce the action of nitric oxide. J. Thromb. Haemost. 5 Supplement 2 (2007) P-M-263
77. Dixon L.J., Hughes S.M., Rooney K., et al. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am. J. Hypertens. 18 (2005) 839-843
78. Joffers M.R., Reed D.M., and Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu Heart Study. Am. J. Clin. Nutr. 5 (1987) 469-475
79. Elin R.J. Assessment of magnesium status. Clin. Chem. 33 (1987) 1965-1970
80. Guzik T.J., Korbut R., and Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J. Physiol. Pharmacol. 54 (2003) 469-487
81. Guzik T.J., and Harrison D.G. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 11 (2006) 524-533
82. Tandon R., Sinha M.K., Garg H., et al. Oxidative stress in patients with essential hypertension. Natl. Med. J. India 18 (2005) 297-299
83. Leoncini G., Maresca M., and Colao C. Oxidative metabolism of human platelets. Biochem. Int. 25 (1991) 647-655
84. El Haouari M., Lopez J.J., Mekhfi H., et al. Antiaggregant effects of Arbutus unedo extracts in human platelets. J. Ethnopharmacol. 113 (2007) 325-331
85. Iuliano L., Colavita A.R., Leo R., et al. Oxygen free radicals and platelet activation. Free Radic. Biol. Med. 22 (1997) 999-1006
86. Seno T., Inoue N., Gao D., et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb. Res. 103 (2001) 399-409
87. Wachowicz B., Olas B., Zbikowska H.M., et al. Generation of reactive oxygen species in blood platelets. Platelets 13 (2002) 175-182
88. Stokes K.Y., Russell J.M., Jennings M.H., et al. Platelet-associated NAD (P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic. Biol. Med. 43 (2007) 22-30
89. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82 (2002) 47-95
90. Rosado J.A., González A., Salido G.M., et al. Effects of reactive oxygen species on actin filament polymerisation and amylase secretion in mouse pancreatic acinar cells. Cell. Signal. 14 (2002) 547-556
91. Chlopicki S., Olszanecki R., Janiszewski M., et al. Functional role of NADPH oxidase in activation of platelets. Antioxid. Redox Signal. 6 (2004) 691-698
92. Krotz F., Sohn H.Y., and Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1988-1996
93. Pignatelli P., Sanguigni V., Lenti L., et al. gp91phox-dependent expression of platelet CD40 ligand. Circulation 110 (2004) 1326-1329
94. Begonja A.J., Gambaryan S., Geiger J., et al. Platelet NAD (P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood 106 (2005) 2757-2760
95. Pignatelli P., Pulcinelli F.M., Lenti L., et al. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 91 (1998) 484-490
96. Abe J., Takahashi M., Ishida M., et al. c-Src is required for oxidative stress-mediated activation of big mitogen-activated protein kinase 1. J. Biol. Chem. 272 (1997) 20389-20394
97. Finkel T. Oxygen radicals and signaling. Curr. Opin. Cell Biol. 10 (1998) 248-253
98. 2+ entry in human platelets. Cell. Signal. 17 (2005) 1011-1021
99. Wolin M.S. Interactions of oxidants with vascular signaling systems. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1430-1442
100. Bouloumie A., Bauersachs J., Linz W., et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension 30 (1997) 934-941
101. Keaney Jr. J.F., and Loscalzo J. Diabetes, oxidative stress, and platelet activation. Circulation 99 (1999) 189-191
102. Hyslop S., and de Nucci G. The mechanisms and significance of the coupled release of endothelium-derived relaxing factor (EDRF) and prostacyclin (PGI2) from endothelial cells. Wien Klin. Wochenschr. 103 (1991) 422-434
103. Radomski M.W., Palmer R.M., and Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 5193-5197
104. Lieberman E.H., O'Neill S., and Mendelsohn M.E. S-nitrosocysteine inhibition of human platelet secretion is correlated with increases in platelet cGMP levels. Circ. Res. 68 (1991) 1722-1728
105. Sneddon J.M., and Vane J.R. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 2800-2804
106. Gries A., Bode C., Peter K., et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 97 (1998) 1481-1487
107. Mendelsohn M.E., O'Neill S., George D., et al. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J. Biol. Chem. 265 (1990) 19028-19034
108. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109-142
109. Dubey R.K., Jackson E.K., and Luscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J. Clin. Invest. 96 (1995) 141-149
110. Riddell D.R., and Owen J.S. Nitric oxide and platelet aggregation. Vitam. Horm. 57 (1999) 25-48
111. Wink D.A., and Mitchell J.B. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 25 (1998) 434-456
112. Schwarz U.R., Walter U., and Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem. Pharmacol. 62 (2001) 1153-1161
113. Rosado J.A., Porras T., Conde M., et al. Cyclic nucleotides modulate store-mediated calcium entry through the activation of protein-tyrosine phosphatases and altered actin polymerization in human platelets. J. Biol. Chem. 276 (2001) 15666-15675
114. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75 (1995) 725-748
115. Schmidt H.H., Lohmann S.M., and Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim. Biophys. Acta 1178 (1993) 153-175
116. Lincoln T.M., Komalavilas P., and Cornwell T.L. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hypertension 23 (1994) 1141-1147
117. Eigenthaler M., Nolte C., Halbrugge M., et al. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur. J. Biochem. 205 (1992) 471-481
118. Horstrup K., Jablonka B., Honig-Liedl P., et al. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur. J. Biochem. 225 (1994) 21-27
119. Lee H.C., and Aarhus R. A derivative of NADP mobilizes calcium stores insensitive to inositol trisphosphate and cyclic ADP-ribose. J. Biol. Chem. 270 (1995) 2152-2157
120. Aszodi A., Pfeifer A., Ahmad M., et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 18 (1999) 37-48
121. Bereczki C., Tur S., Nemeth I., et al. The roles of platelet function, thromboxane, blood lipids and nitric oxide in hypertension of children and adolescents. Prostaglandins Leukot. Essent 62 (2000) 293-297
122. Cadwgan T.M., and Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J. Hypertens. 11 (1993) 417-420
123. Moss M.B., Brunini T.M., Soares De Moura R., et al. Diminishedl-arginine bioavailability in hypertension. Clin. Sci. (Lond.) 107 (2004) 391-397
124. Gtyglewski R.J., Palmer R.M.J., and Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature 320 (1986) 454-456
125. Handin R.I., Karabin P., and Boxer G.J. Enhancement of platelet function by superoxide anion. J. Clin. Invest. 59 (1977) 959-965
126. Plumb R.D., El-Sherbeeny N.A., Dixon L.J., et al. NAD (P)H-dependent superoxide production in platelets: the role of angiotensin II and protein kinase C. Clin. Biochem. 38 (2005) 607-613
127. Mehta J.L., Lopez L.M., Chen L., et al. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am. J. Cardiol. 74 (1994) 901-905
128. Nityanand S., Tekwani B.L., Chandra M., et al. Kinetics of serotonin in platelets in essential hypertension. Life Sci. 46 (1990) 367-372
129. 2+ concentration and plasma cholesterol in untreated hypertensives. J. Hypertens. Suppl. 5 (1987) S251-254
130. Ferroni P., Martini F., D'Alessandro R., et al. In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. Clin. Chim. Acta. 388 (2008) 33-37
131. Mehta J., and Mehta P. Platelet function in hypertension and effect of therapy. Am. J. Cardiol. 47 (1981) 331-334
132. Maly J., Pecka M., Pinterova E., et al. Changes in platelet function in patients with arterial hypertension. Vnitr Lek. 41 (1995) 458-461
133. Vlachakis N.D., and Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atherosclerosis 32 (1979) 451-460
134. Nyrop M. Platelet function, hypertension and ischemic heart disease. Ugeskr Laeger. 151 (1989) 2504-2507